November 13, 2026

The Manager (Listing),
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: AVIENCE

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Investors / Earnings Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, please find attached herewith Investors/ Earnings Presentation in connection with Earnings Conference Call for investors scheduled as on Tuesday, November 17, 2026 at 01.00 P.M. (IST) to discuss the Unaudited Financial Results for HY1 of FY 2026-27.

The above information is also available on the website of the Company i.e., **https://avienbio.com/**

Kindly take the same on records.

Thanking you,
Yours faithfully.

For **AVIENCE BIOMEDICALS LIMITED**

DHARAM DEO CHOUDHARY

DHARAM DEO CHOUDHARY
Managing Director
DIN- 02804625
Address: Flat No 48, Suryodaya Apartment, Pocket 8,
Sec-12, Dwarka, Dist: South West Delhi, Delhi – 110078

Encl: As above

AVIENbio®
Complete Healthcare Solution

AVIENCE BIOMEDICALS LIMITED

H1 FY27 | INVESTOR PRESENTATION





DISCLAIMER

This presentation has been prepared by Avience Biomedicals Limited solely for informational purposes. The information contained herein is intended to provide a general overview of the Company, its business operations, products, services, industry and growth strategy. It does not constitute an offer, invitation, recommendation or solicitation to purchase or subscribe for any securities or other financial instruments, nor should it be construed as investment, legal, accounting, regulatory or tax advice. Certain information, illustrations, graphics, photographs and visuals contained in this presentation are intended for illustrative purposes only and may not represent the Company's actual products, facilities, operations or future performance. While reasonable care has been taken in preparing this presentation and the information is believed to be accurate as of the date of publication, Avience Biomedicals Limited makes no representation or warranty, express or implied, regarding the accuracy, completeness or reliability of the information contained herein. The Company, its directors, officers, employees and advisors shall not be liable for any direct or indirect loss arising from the use of, or reliance upon, this presentation. This presentation may contain forward-looking statements relating to the Company's business prospects, expansion plans, manufacturing capabilities, product portfolio, market opportunities, financial performance and growth strategy. Such statements are based on current expectations and assumptions and are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update or revise any forward-looking statements to reflect future events or developments. Any industry data, market information or third-party reports referred to in this presentation have been obtained from publicly available sources believed to be reliable. However, such information has not been independently verified by the Company, and no representation is made regarding its accuracy or completeness. Recipients are advised to conduct their own independent evaluation of the Company and seek appropriate professional advice before making any business, financial or investment decisions based on the information contained in this presentation.

COMPANY SNAPSHOT

Avience Biomedicals Limited

is an integrated diagnostics and medical devices company engaged in manufacturing, distribution, and marketing of **IVD products, medical devices, reagents, analyzers,** and medical consumables across India.

ivd and medical device products



ESTABLISHED
2019
Year of Incorporation

MANUFACTURING FACILITY
NOIDA
Uttar Pradesh

PRODUCT PORTFOLIO
ivd and medical device products , regents analyzer and consumables
IVD Kits, Reagents, Analyzers & Consumables

CDSCO APPROVALS
117
Approved Products

PRODUCT PIPELINE
200+
Applications Under Process

BUSINESS MODEL
Manufacturing + Distribution

PRESENCE
PAN INDIA
Network

CUSTOMERS
Government & Private Healthcare Institutions

QUALITY CERTIFICATIONS
ISO 13485:2016,
ISO 9001:2015

MANUFACTURING FACILITY
State-of-the-art facility in Noida, Uttar Pradesh

EXPANSION
Medical Device Park at **YEIDA**, Uttar Pradesh

STRATEGIC PARTNERSHIP
Authorized Distributor for Mindray in India

BUSINESS MODEL

01



MANUFACTURING OF

- IVD and Medical Device Products
- Reagents
- Consumables
- Diagnostic Products

02



DISTRIBUTION & STRATEGIC PARTNERSHIPS

Pan India distribution network and strategic collaborations

03



PLACEMENT OF DIAGNOSTIC INSTRUMENTS / ANALYZERS

Installed at customer locations

04



RECURRING CONSUMABLES & REAGENT REVENUE

Repeat purchases driving sustainable revenue

05



LONG-TERM INSTITUTIONAL CUSTOMER RELATIONSHIPS

Strong trust, retention and long-term growth

SCALABLE RECURRING REVENUE MODEL

- Consumables-driven repeat business
- Strong customer retention
- High operating leverage potential
- Integrated manufacturing + distribution ecosystem

SERVING A DIVERSE CUSTOMER BASE


- GOVERNMENT & PRIVATE HOSPITALS
- GOVERNMENT & PRIVATE LABS
- DIAGNOSTIC CENTERS
- HEALTHCARE INSTITUTIONS

H1 FY27 PERFORMANCE SNAPSHOT


VIENbio®
Complete Healthcare Solution

Robust Growth in Revenue, EBITDA and Profitability


REVENUE
(₹ Lakhs)



EBITDA
(₹ Lakhs)



PAT
(₹ Lakhs)




MARGIN PERFORMANCE


Healthy Margins Driven by Operational Efficiency

VIENbio®
Complete Healthcare Solution

EBITDA MARGIN



PAT MARGIN



MANAGEMENT COMMENTARY



Mr. Dharam Deo Choudhary
Promoter & Managing Director
Avience Biomedicals Limited

"H1 FY27 has been a period of steady and profitable growth for Avience Biomedicals, reflecting strong execution of our business strategy. Revenue from operations grew **16.07% YoY to ₹31.13 Cr**, EBITDA increased **15.60% to ₹8.38 Cr**, while PAT grew **22.00% to ₹5.54 Cr**. We maintained a healthy EBITDA margin of **26.93%**, while PAT margin improved to **17.78%**, reflecting disciplined execution and a favourable product mix.

We are pleased to share that construction of our **fully automated manufacturing facility at YEIDA Medical Device Park, Yamuna Expressway, is on track for completion by Jan - 27**, and the facility is set to be inaugurated shortly. This facility will significantly enhance our manufacturing capabilities, particularly in biochemistry analysers and reagents, while providing the scale to cater to growing institutional demand.

Product portfolio expansion remains central to our growth strategy. We currently hold **117 CDSCO manufacturing licences** across biochemistry, rapid diagnostics, haematology and microbiology, supported by a strong pipeline of over **200 products under regulatory approval**. As these approvals come through, we intend to progressively launch new products and expand into additional diagnostic categories. Our analyser placements, supported by our authorised distributorship of Mindray in India, continue to strengthen recurring revenue opportunities from reagents and consumables.

We remain committed to building a high-quality, scalable and globally competitive diagnostics company, delivering innovative and affordable healthcare solutions while creating sustainable long-term value for our customers, partners and shareholders."

REVENUE MIX – DOMESTIC vs EXPORT

Expanding Global Reach. Strengthening Our Presence.


Particulars	FY26 Share (%)	H1 FY27 Share (%)
Domestic	98.99%	86.47%
Exports	1.01%	13.53%
Total	100.00%	100.00%

FY26

- Domestic 98.99%
- Exports 1.01%



Exports increased by **12.52** percentage points



H1 FY27


- Domestic 86.47%
- Exports 13.53%

Export contribution increased from **1.01%** in FY26 to **13.53%** in H1 FY27, reflecting our growing global presence.

REVENUE MIX – MANUFACTURING vs TRADING

Manufacturing Scales Higher, with Moderation in Trading Growth

Particulars	H1 FY26 (₹ Lakhs)	H1 FY27 (₹ Lakhs)	Growth (%)
Manufacturing (MFG)	647.53	1,122.62	+73.36%
Trading	2,034.37	1,990.24	−2.17%
Total Revenue	**2,681.90**	**3,112.86**	**+16.12%**



Manufacturing revenue increased by **73.36%** to **₹1,122.62 lakhs**, while trading declined slightly by **2.17%** to **₹1,990.24 lakhs**.

MEET OUR TEAM



Mr. Dharam Deo Choudhary

Promoter & Managing Director

- Educational background includes a Bachelor of Commerce and member of ICMAI.
- 30 years of experience across accounts, finance, and business management with deep strategic and financial expertise.
- 25-year tenure as Director of M/s DR Meditech Surgical and Diagnostics India Pvt. Ltd., with deep understanding of the IVD business.
- Committed to operational efficiency, financial sustainability, and strategic decision-making to drive the company's growth.

MEET OUR TEAM



Mrs. Deepa Choudhary

Promoter & Executive Director

- Aged 37 years, holds a Bachelor of Arts degree from Chhatrapati Shahu ji Maharaj University, Kanpur.
- 5 years of experience in formulating and implementing strategic business development.
- Expert in market analysis, relationship building, and strategic planning.
- Identifies new opportunities and ensures consistent success.



CA. Om Prakash Pal

Independent Director

- Practicing Chartered Accountant.
- 16+ years of experience in Audit, Direct Taxation, Finance & Consultancy.
- Strong expertise in financial strategy, regulatory compliance & tax planning.
- Advises the board to improve financial discipline and transparency.



Mr. Janardan Pal

Promoter & Non-Executive Director

- Aged 43 years, holds a Bachelor of Commerce degree from the University of Delhi (2005).
- 13 years of experience in strategic planning and guiding operational initiatives.
- Serving the company since its incorporation and plays a key role in shaping strategic direction.



Mr. Pankaj Sharma

Independent Director

- B.Tech (Chemical Engineering) from IIT Delhi and M.S. (Consultancy Management) from BITS Pilani.
- 30+ years of experience in business management, engineering, project execution, and entrepreneurship.
- Worked with reputed organizations such as C2C Technosoft, UOP India Pvt. Ltd., and Foster Wheeler Energy Ltd.
- Contributes strong strategic thinking, technical expertise, and governance oversight.



Mr. Ram Nagina Choudhary

Promoter & Whole Time Director

- Seasoned professional with over 22 years of experience in daily operations, managing logistics, and execution of supply chain.
- Serving as Director of Avience Biomedicals Limited, bringing expertise in surgical and diagnostic distribution.
- 15-year tenure as Director of M/s DR Meditech Surgical and Diagnostics India Pvt. Ltd.
- Strong background in supply chain management, operations, customer care, procurement, and business administration.

PRODUCT ECOSYSTEM

AVIENbio®
Complete Healthcare Solution

IVD KITS

- Rapid Test Kits
- Diagnostic Test Kits
- Screening Products



REAGENTS

- Biochemistry Reagents
- Hematology Reagents
- Diagnostic Solutions



DIAGNOSTIC INSTRUMENTS

- Analyzers
- Electrolyte Systems
- Automated Diagnostic Equipment



Integrated Diagnostics & Medical Devices Platform

MEDICAL CONSUMABLES

- Sample Collection Products
- Tubes & Accessories
- Lab Consumables



MOLECULAR DIAGNOSTICS

- PCR Related Products
- Advanced Diagnostic Solutions



HEALTHCARE SOLUTIONS

- Institutional Supply
- Government Healthcare Support



WIDE RANGE OF QUALITY PRODUCTS | **INTEGRATED MANUFACTURING** | **STRONG R&D & INNOVATION FOCUS** | **HIGH QUALITY & REGULATORY COMPLIANCE** | **PAN INDIA PRESENCE ACROSS SEGMENTS**

JOURNEY OF GROWTH

AVIENbio®
Complete Healthcare Solution

2019

Incorporation of Avience Biomedicals

- Incorporated on 23 December 2019

2020

Expansion of Product Portfolio

- IVD Kits
- Reagents & Consumables
- Diagnostic Solutions

2022

Strengthening Manufacturing Capabilities

- Expansion of manufacturing operations
- Enhanced regulatory compliance framework

2024

Corporate Milestone

- Conversion into Public Limited Company
- Renamed as Avience Biomedicals Limited

2025

Product & Regulatory Expansion

- Growing CDSCO approved product portfolio
- Continued product registrations and applications

2026+

Next Phase of Growth

- Fully Automated Medical Device Park Facility
- Capacity expansion across product categories

BUILDING AN INTEGRATED DIAGNOSTICS, MEDICAL DEVICES & HEALTHCARE SOLUTIONS PLATFORM

- WIDE RANGE OF QUALITY PRODUCTS
- INTEGRATED MANUFACTURING
- STRONG R&D & INNOVATION FOCUS
- HIGH QUALITY & REGULATORY COMPLIANCE
- NATIONWIDE CUSTOMER REACH ACROSS INDIA

MANUFACTURED PRODUCTS – COMPLETE DIAGNOSTIC SOLUTIONS

AVIENbio® Complete Healthcare Solution

RAPID TEST KITS

Avisure Pregnancy Card



Avisure Pregnancy Strip



MOLECULAR

Covid-19 Hid RTqPCR ASSAY



H1N1 Swine Flu



CULTURE MEDIA

Viral Transport Solution



BIOCHEMISTRY ANALYZER

Avience Biochemistry



OXYGEN CONCENTRATOR

JAY-5AW



JAY-10



ELECTROLYTE ANALYZER & REAGENTS

AV Lyte 80 Analyzer



AV Lyte 90 Analyzer



HAEMATOLOGY ANALYZER & REAGENTS

3 Part Auto Haematology Analyzer



LYSE



Blood Cell Diluent




Avienbio's manufactured products empower healthcare professionals with accurate diagnostics, efficient workflows and better patient outcomes.

MANUFACTURING & QUALITY CONTROL

AVIENbio®
Complete Healthcare Solution

MANUFACTURING FACILITY



MANUFACTURING PROCESS



MANUFACTURING PROCESS



ASSEMBLING PROCESS FOR RAPID TEST KITS




PACKAGING POUCHES FOR RAPID TEST KITS



ASSEMBLY OF BIOCHEMISTRY MACHINE



QUALITY TESTING MACHINE FOR RAPID TEST KITS



EXPANSION PLAN

Scaling Manufacturing Capabilities for the Next Phase of Growth

AVIENbio® Complete Healthocre Solution



Proposed Manufacturing Facility
Medical Device Park (YEIDA), Gautam Buddha Nagar, Uttar Pradesh

Location
Plot No. 70, Sector 28, YEIDA Medical Device Park

Land Area
2,100 Sq. Meters

Manufacturing Focus
Biochemistry Analyzer Manufacturing

Facility Type
Fully Automated Manufacturing Facility

Target Commissioning
Jan - 27

₹ 30.18 cr
Total Project Investment

FUNDING MIX

IPO Proceeds	₹15.95 Cr.
SIDBI Funding	₹12.00 Cr.
Internal Accruals	₹2.23 Cr.

STRATEGIC OBJECTIVES

- Expand Manufacturing Infrastructure
- Increase Production Capacity
- Support Product Diversification
- Strengthen Presence in Medical Devices
- Enhance Service to Hospitals, Laboratories & Research Institutions
- Capture Growth Opportunities in India's Diagnostics Industry

EXPECTED BENEFITS

- Higher Manufacturing Scale
- Improved Operational Efficiency
- Dedicated Analyzer Manufacturing Capability
- Enhanced Domestic & Export Potential
- Strong Platform for Long-Term Growth

Avience is investing **₹30.18 crore** in a fully automated manufacturing facility at YEIDA Medical Device Park, with operations targeted by **Jan - 27**

CDSCO MANUFACTURING LICENSE PROCESS

VIENbio®
Complete Healthcare Solution

1 DOCUMENT COLLECTION



Collation of documents for obtaining test license

2 APPLICATION SUBMISSION



Submission of application for test license

3 TEST LICENSE ISSUED



Issue of test license by CDSCO

4 PRODUCT MANUFACTURING



Manufacturing of the product

5 PRODUCT TESTING



Product testing through accredited laboratories

6 PRODUCT APPROVAL



Approval of product

7 MANUFACTURING LICENSE APPLICATION



Submission of application for manufacturing license

8 REGULATORY EVALUATION



Evaluation based on manufacturing track record and market standing certificate

9 MANUFACTURING LICENSE ISSUED



Issue of manufacturing license by CDSCO



AVERAGE TIMELINE

9–12 MONTHS



REGULATORY AUTHORITY

CDSCO

KEY TAKEAWAY

Manufacturing license approval involves multiple regulatory, testing and compliance stages, creating significant entry barriers and strengthening the competitive position of approved manufacturers.

CDSCO LICENSED PRODUCT PORTFOLIO

117 CDSCO Manufacturing Licenses Across Multiple Diagnostic Categories

AVIENbio®
Complete Healthcare Solution

BIOCHEMISTRY PRODUCTS — 43 Licenses



- Biochemistry Analyzers
- Glucose, Urea, Creatinine & Cholesterol Reagents
- Liver Function & Protein Testing Reagents
- Electrolyte Analyzers
- Laboratory Consumables & Collection Tubes

RAPID DIAGNOSTIC TEST KITS — 24 Licenses



- Dengue NS1 & Combo Test
- Malaria Pf/Pv & Pf/Pan Test
- HIV 1/2 Antibody Test
- HBsAg Test
- HCV Antibody Test
- Typhoid Test
- Syphilis Test
- Pregnancy Test Kits
- H. Pylori, Leptospira, Scrub Typhus & Others

HEMATOLOGY PRODUCTS



- Probe Cleaner
- Blood Cell Diluent
- LYSE Reagents

MICROBIOLOGY PRODUCTS



- Viral Transport Medium (VTM)

LICENSING ADVANTAGE

- 117 CDSCO Manufacturing Licenses Already Obtained
- Covers Diagnostics, Reagents, Consumables & Medical Devices
- Applications Under Process For **200+** Additional Products
- Strong Regulatory Entry Barrier For New Competitors

KEY TAKEAWAY

> Broad CDSCO-approved product portfolio enables Avience to offer end-to-end diagnostic solutions while creating a strong regulatory moat in the Indian diagnostics market.

117
CDSCO Licenses

4 Categories
Diagnostic Segments

200+
Products
Under Approval

CUSTOMER & DISTRIBUTION NETWORK

PAN INDIA DISTRIBUTION PRESENCE

EXPANDING REACH
ACROSS MULTIPLE STATES

STRONG DISTRIBUTION
& CHANNEL NETWORK

INSTITUTIONAL &
HEALTHCARE FOCUSED
ECOSYSTEM

EFFICIENT PRODUCT
SUPPLY & SERVICE
SUPPORT



OUR CUSTOMER SEGMENTS

GOVERNMENT HOSPITALS



PRIVATE HOSPITALS



DIAGNOSTIC LABORATORIES



HEALTHCARE INSTITUTIONS



RESEARCH CENTERS



DISTRIBUTION PARTNERS



Strong customer relationships and distribution capabilities support **recurring business growth.**

PAN INDIA
REACH

WIDE INSTITUTIONAL
RELATIONSHIPS

REPEAT BUSINESS
DRIVEN MODEL


STRONG SERVICE
SUPPORT NETWORK

SCALABLE CUSTOMER
ECOSYSTEM

INDUSTRY OUTLOOK


India's Diagnostics Industry Positioned for Strong Long Term Growth

Indian diagnostics market – In vitro vs In vivo (INR B, FY20-30P)



	CAGR (FY20-25)	CAGR (FY25-30P)
In vitro	11.5%	11.2%
In vivo	10.4%	12.0%

Indian IVD market by techniques (INR B, FY20-30P)



	CAGR (FY20-25)	CAGR (FY25-30P)
Immunodiagnostics	14.5%	14.0%
Hematology	8.4%	8.5%
Molecular diagnostics	13.7%	17.0%
Clinical Chemistry	9.3%	11.0%
Others	10.9%	12.5%

Source: Lattice Analysis

MARKET SNAPSHOT

- Indian diagnostics market expected to reach **₹ 1,964 Billion by FY30P**
- Industry projected to grow at **11%+ CAGR** through FY30P

KEY GROWTH DRIVERS

- **Rising disease burden:** TB • Diabetes • Cancer • Cardiovascular Diseases
- Rapid adoption of **molecular diagnostics**
- **AI automation & digital reporting** driving efficiency and accuracy
- **Government initiatives** and diagnostics expansion (NHM, Free Diagnostics Services)
- Increasing **health insurance penetration** (25% → 51%) improving affordability
- Expansion of organised diagnostic chains into **Tier-2 / Tier-3 markets**

LEADING PLAYERS

Roche · Abbott · SIEMENS Healthineers · TRANSASIA (No.1 Diagnostic Company in India) · BECKMAN COULTER

India's diagnostics industry is expected to witness sustained double digit growth, driven by rising healthcare awareness, technological advancements and expanding access to diagnostic services.

COMPETITIVE STRENGTHS

1

INTEGRATED MANUFACTURING & DISTRIBUTION PLATFORM



2 117 CDSCO

APPROVED PRODUCTS

WITH STRONG REGULATORY CAPABILITIES



3

RECURRING CONSUMABLES-LED REVENUE MODEL



4 STRONG

INSTITUTIONAL PRESENCE

ACROSS GOVERNMENT & PRIVATE HEALTHCARE



5

EXPANSION THROUGH FULLY AUTOMATED MEDICAL DEVICE PARK FACILITY



6

WELL POSITIONED TO BENEFIT FROM IMPORT SUBSTITUTION & MAKE IN INDIA



QUALITY CERTIFICATIONS | PAN INDIA PRESENCE | STRATEGIC PARTNERSHIPS | ROBUST PRODUCT PIPELINE | SCALABLE OPERATIONS

INVESTMENT RATIONALE

VIENbio® Complete Healthcare Solution

Well Positioned to Capitalize on India's Growing Diagnostics & Healthcare Opportunity



Diversified Portfolio

Offering a comprehensive range of diagnostics, medical devices, analyzers and healthcare consumables across multiple healthcare segments.



117 CDSCO Approvals

Strong regulatory credentials with approved products supporting market credibility and business growth.



Planned Product Expansion

The Company intends to expand its product portfolio through 200+ applications planned for submission and regulatory review over time.



Pan-India Network

Established distribution network serving customers across multiple states and healthcare markets across India.



Recurring Revenue Model

Consumables and reagents business generates repeat orders, enhancing revenue visibility and business stability.



Manufacturing Strength

Integrated manufacturing capabilities supported by quality control systems and regulatory compliance standards.



Expansion Focused

Upcoming manufacturing facility expected to strengthen capacity, operational efficiency and future scalability.



B2B Healthcare Focus


Serving hospitals, pathology laboratories, research institutions and healthcare organizations across the country.

CERTIFICATIONS, COMPLIANCE & QUALITY EXCELLENCE

Globally Recognized Standards. Quality Assured. Built for Trust.

AVIENbio® Complete Healthcare Solution

1. ISO 13485:2016 (IAF MLA)



Certificate of Registration

AVIENCE BIOMEDICALS LIMITED

G-1, SECOTR-11, NOIDA, GAUTAM BUDDH NAGAR, UTTAR PRADESH-201301, INDIA

has been assessed and Certified by Otabu Certification Pvt. Ltd.

as meeting the requirements of:

ISO 13485:2016

Quality Management System for Medical Devices

For the following scope of activities:

Issue No: 01
Date of Certification: 22 July 2025
1st Surveillance Due: 21 July 2026

Revision No( ) : NA
2nd Surveillance Due: 21 July 2027
Recertification Due: 21 July 2028
(subject to the company maintaining its system to the required standard)

Certificate Number: 0722QMMD424725

Validity of this certificate can be verified at www.otabucert.com

IAF · EGAC 13500A · Otabu Certification Private Limited


Dr. Anita Gupta
Managing Director

"Validity of the certificate is subject to successful completion of surveillance audit on or before due date (in case surveillance audit is not allowed to be conducted, this certificate shall be suspended/withdrawal). "This Certificate of Registration remains the Property of Otabu Certification Pvt. Ltd. and shall be returned immediately upon request.

Quality Management System for Medical Devices

- IAF MLA Recognized
- International Medical Device Quality Standard
- Covers Manufacturing & Supply of Diagnostic Products

2. ISO 9001:2015 (AF MLA)



Certificate of Registration

AVIENCE BIOMEDICALS LIMITED

G-1, SECOTR-11, NOIDA, GAUTAM BUDDH NAGAR, UTTAR PRADESH-201301, INDIA

has been assessed and Certified by Otabu Certification Pvt. Ltd.

as meeting the requirements of:

ISO 9001:2015

Quality Management System

For the following scope of activities:

Issue No: 01
Date of Certification: 22 July 2025
1st Surveillance Due: 21 July 2026

Revision No( ) : NA
2nd Surveillance Due: 21 July 2027
Recertification Due: 21 July 2028
(subject to the company maintaining its system to the required standard)

Certificate Number: 0722Q424625

Validity of this certificate can be verified at www.otabucert.com

IAF · EGAC 13500A · Otabu Certification Private Limited

Dr. Anita Gupta
(Managing Director)

"Validity of the certificate is subject to successful completion of surveillance audit on or before due date (in case surveillance audit is not allowed to be conducted, this certificate shall be suspended/withdrawal). "This Certificate of Registration remains the Property of Otabu Certification Pvt. Ltd. and shall be returned immediately upon request.

Otabu Certification Pvt. Ltd., 82 6 (Ground Floor), Prem Nagar, Uttam Nagar, New Delhi-110059 (India)

Email:- info@otabucert.com website:-www.otabucert.com

Quality Management System

- IAF MLA Recognized
- Standardized Quality Processes
- Continuous Improvement Framework

3. CE CERTIFICATION (UK CERT LTD)



Certificate of Compliance

CE

AVIENCE BIOMEDICALS LIMITED

This is to certify that the technical file of above mentioned product has been reviewed and found to comply with the medical devices directive 93/42/EEC

Manufacturer
Name : AVIENCE BIOMEDICALS LIMITED
Address : UNIT 01, G-1, SECTOR-11, NOIDA, DISTT. GAUTAM BUDDHA NAGAR, UTTAR PRADESH, INDIA
UNIT 02: UNIT NO.: 15TH FLOOR, C-11, C BLOCK, COMMUNITY CENTRE, JANAKPURI, NEW DELHI-110000, INDIA

Product : MANUFACTURE AND DISTRIBUTION OF IN-VITRO DIAGNOSTIC REAGENTS, INSTRUMENTS, SEMI AUTOMATED CLINICAL HEMATOLOGY ANALYZER, COAGULATION ANALYZER, BIOCHEMISTRY ANALYZER, ELECTROLYTE ANALYZER, PPE KITS, VENTILATOR, PATIENT MONITOR, ANESTHESIA WORKSTATION, HIGH FREQUENCY CANNULA THERAPY, BT PCR KIT, VTM KIT, INFRARED THERMOMETER, MOLECULAR KIT, OXYGEN CONCENTRATOR, RAPID DIAGNOSTIC KIT, MALARIA KIT, DENGUE KIT, HIV KIT, HCV KIT, TYPHOID & DISPOSABLE PRODUCTS

Date of Registration	10 November 2023
1st Surveillance Due	09 November 2024
2nd Surveillance Due	09 November 2025
Certificate Expiry	09 November 2026

UK Cert Limited (UK)
5 Jupiter House, Calleva Park, Aldermaston, Reading Berkshire RG7 8NN, UK
Website:- www.ukcert.co.uk | Email:- info@ukcert.co.uk

Authorised Signatory

Affirms conformity with European health, safety & environmental protection standards

- European Conformity Certification
- Health, Safety & Environmental Compliance
- Supports International Market Access

4. WHO-GMP COMPLIANCE CERTIFICATE (UK CERT LTD)



Certificate of Compliance

CE

AVIENCE BIOMEDICALS LIMITED

WHO-GMP

Has been successfully implemented the Quality management System and found working satisfactorily as per the norms of "Good Manufacturing Practice"

MANUFACTURE AND DISTRIBUTION OF IN-VITRO DIAGNOSTIC REAGENTS, INSTRUMENTS, SEMI AUTOMATED CLINICAL HEMATOLOGY ANALYZER, BIOCHEMISTRY ANALYZER, COAGULATION ANALYZER, ELECTROLYTE ANALYZER, PPE KITS, VENTILATOR, PATIENT MONITOR, ANESTHESIA WORKSTATION, HIGH FREQUENCY CANNULA THERAPY, BT PCR KIT, VTM KIT, INFRARED THERMOMETER, MOLECULAR KIT, OXYGEN CONCENTRATOR, RAPID DIAGNOSTIC KIT, MALARIA KIT, DENGUE KIT, HIV KIT, HCV KIT, TYPHOID & DISPOSABLE MEDICAL PRODUCTS

Certificate Number: 402101123

Date of Registration	10 November 2023
1st Surveillance Due	09 November 2024
2nd Surveillance Due	08 November 2025
Certificate Expiry	09 November 2026

UK Cert Limited (UK)
5 Jupiter House, Calleva Park, Aldermaston, Reading Berkshire RG7 8NN, UK

Authorised Signatory

Quality Management system satisfactorily as per the norms of "Good Manufacturing Practice"

- Good Manufacturing Practice (GMP) Compliant
- Quality Management System Verified
- Covers Diagnostic Reagents, Kits & Medical Devices

5. GeM & QCI VENDOR ASSESSMENT REPORT



VENDOR ASSESSMENT REPORT

March 17th, 2021

AVIENCE BIOMEDICALS PRIVATE LIMITED

VA-374250623124784

GeM Government e Marketplace
Efficient • Transparent • Inclusive

QUALITY COUNCIL OF INDIA
Creating an Ecosystem for Quality

- Assessed by Quality Council of India (QCI)
- Government e Marketplace (GeM) Verified
- Vendor Quality & Process Assessment Completed

6. ZED GOLD CERTIFICATE



भूक्ष्म, लघु और मध्यम उद्यम मंत्रालय
MINISTRY OF MICRO, SMALL & MEDIUM ENTERPRISES

ZED GOLD

CERTIFICATE

ZED GOLD

under MSME Sustainable (ZED) Certification Scheme
awarded to

AVIENCE BIOMEDICALS PRIVATE LIMITED

Plot No:- G-1, Building:- SECTOR-11, Road/Street:- GAUTAM BUDDHA NAGAR, Village/Town:- NOIDA, Block:- GAUTAM BUDDHA NAGAR, City:- NOIDA, GAUTAM BUDDHA NAGAR, UTTAR PRADESH-201301

21-Manufacture of pharmaceuticals, medicinal chemical and botanical products

UDYAM-DL-11-0002440

Quality Austria Control Asia Private Limited

Issued on :
February 10, 2024

Certificate No. 10000004_000005

- MSME Sustainable Manufacturing Recognition
- Zero Defect Zero Effect (ZED)
- Focus on Quality, Sustainability & Operational Excellence

REGULATORY & QUALITY EXCELLENCE

REGULATORY STRENGTH

117
CDSCO
APPROVED PRODUCTS



117 CDSCO APPROVED PRODUCTS

200+ APPLICATIONS UNDER PROCESS

STRONG UNDERSTANDING OF REGULATORY FRAMEWORK

PRODUCT APPROVAL EXPERTISE ACROSS MULTIPLE DIAGNOSTIC CATEGORIES

REGULATORY APPROVAL JOURNEY

APPLICATION → TESTING & EVALUATION → DOCUMENTATION REVIEW → APPROVAL → COMMERCIALIZATION

MEDICAL DEVICE APPROVALS INVOLVE LENGTHY REGULATORY PROCESSES, CREATING STRONG ENTRY BARRIERS FOR NEW PLAYERS.

QUALITY & COMPLIANCE

ISO 13485:2016
CERTIFIED

ISO 9001:2015
CERTIFIED

QUALITY FOCUSED
MANUFACTURING PROCESSES

COMPLIANCE DRIVEN
PRODUCT DEVELOPMENT

FOCUS ON PRODUCT
RELIABILITY & ACCURACY



BUILDING TRUST THROUGH
REGULATORY EXCELLENCE & QUALITY STANDARDS

WAY FORWARD

AVIENbio®
Complete Healthcare Solution

1. EXPAND MANUFACTURING CAPACITY

Expand Manufacturing Capacity through the upcoming fully automated Medical Device Park facility to support higher volumes and product diversification.



2. ACCELERATE PRODUCT APPROVALS & COMMERCIALIZATION

Accelerate Product Approvals & Commercialization by converting the 200+ product applications under process into market-ready products and strengthening the product portfolio.



3. STRENGTHEN DOMESTIC PRESENCE & BUILD EXPORT MARKETS

Strengthen Domestic Presence & Build Export Markets by deepening penetration across government hospitals, private labs, diagnostic centers, and healthcare institutions while expanding into international markets through strategic partnerships and regulatory approvals.



THANK YOU

Contact Information

Moonwalk Capital IR Team

Phone: +917014618970

E-mail: investorrelations@moonwalkcapitaladvisors.com